Phase II Study of Up-front Chemotherapy and Neo-adjuvant Short-course Radiotherapy for Resectable Rectal Carcinoma (COLORE) (COLORE)
Phase II Study of Up-front Chemotherapy and Neo-adjuvant Short-course Radiotherapy for Resectable Rectal Carcinoma
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
A PHASE2 clinical study on Rectal Carcinoma, this trial is completed. The trial is conducted by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS and has accumulated 12 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Apr 2025 — Present [monthly]
Completed PHASE2
-
Feb 2025 — Apr 2025 [monthly]
Completed PHASE2
-
Sep 2024 — Feb 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jul 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
▶ Show 7 earlier versions
-
Mar 2023 — Jul 2023 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Mar 2021 — Mar 2023 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE2
-
May 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Dec 2018 — May 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Dec 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Oct 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
For direct contact, visit the study record on ClinicalTrials.gov .